Citigroup’s Acrivon Therapeutics ACRV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $38.5K | Buy |
32,382
+21,223
| +190% | +$25.3K | ﹤0.01% | 4161 |
|
|
2025
Q1 | $22.7K | Sell |
11,159
-1,173
| -10% | -$2.38K | ﹤0.01% | 4292 |
|
|
2024
Q4 | $74.2K | Buy |
12,332
+1,116
| +10% | +$6.72K | ﹤0.01% | 4115 |
|
|
2024
Q3 | $78.5K | Buy |
11,216
+6,134
| +121% | +$42.9K | ﹤0.01% | 4099 |
|
|
2024
Q2 | $29.5K | Buy |
5,082
+546
| +12% | +$3.17K | ﹤0.01% | 4137 |
|
|
2024
Q1 | $32.4K | Buy |
4,536
+2,489
| +122% | +$17.8K | ﹤0.01% | 4117 |
|
|
2023
Q4 | $10.1K | Buy |
2,047
+1,817
| +790% | +$8.94K | ﹤0.01% | 4432 |
|
|
2023
Q3 | $2.2K | Sell |
230
-2,560
| -92% | -$24.5K | ﹤0.01% | 4186 |
|
|
2023
Q2 | $36.2K | Buy |
2,790
+2,588
| +1,281% | +$33.5K | ﹤0.01% | 4116 |
|
|
2023
Q1 | $2.56K | Buy |
+202
| New | +$2.56K | ﹤0.01% | 4348 |
|